Feasibility and safety of targeting mitochondria for cancer therapy – preclinical characterization of gamitrinib,a first-in-class,mitochondriaL-targeted small molecule Hsp90 inhibitor |
| |
| Authors: | Umar Hayat Gary T Elliott Anthony J Olszanski Dario C Altieri |
| |
| Institution: | aPharmaceutical Advisors, LLC, Princeton, USA;bGalenic Strategies Inc, Windsor;cPhase 1 Developmental Therapeutics Program, Department of Hematology/Oncology Fox Chase Cancer Center, Philadelphia;dImmunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, USA |
| |
| Abstract: | |
| |
| Keywords: | |
|
|
